PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
149.60%
Cash & equivalents growing 149.60% while AGEN's declined -14.53%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
149.60%
Below half of AGEN's -14.53%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
133.42%
Below half of AGEN's -10.93%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
835.01%
≥ 1.5x AGEN's 9.85%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1079.37%
≥ 1.5x AGEN's 0.34%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
135.47%
Below half of AGEN's -7.49%. Michael Burry sees a potential red flag for stagnation or capital shortage.
69.91%
Less than half of AGEN's -44.70%. David Dodd sees a more disciplined AP approach or lower volume.
-41.82%
Less than half of AGEN's 81.96%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-49.13%
Less than half of AGEN's 16.44%. David Dodd sees fewer expansions in other current obligations.
-44.50%
Less than half of AGEN's 29.20%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-44.50%
Above 1.5x AGEN's -5.47%. Michael Burry sees a potential leverage warning sign.
7.98%
Above 1.5x AGEN's 0.68%. Michael Burry suspects heavy new equity expansion or dilution.
4.22%
Below half AGEN's -1.24%. Michael Burry suspects major net losses or high dividends vs. competitor.
-271.57%
Above 1.5x AGEN's -37.04%. Michael Burry sees a significant jump in intangible or market-based gains. Scrutinize risk of reversal.
No Data
No Data available this quarter, please select a different quarter.
132.15%
Below half AGEN's -8.93%. Michael Burry sees potential underperformance in building shareholder capital.
135.47%
Below half AGEN's -7.49%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-41.82%
Above 1.5x AGEN's -20.64%. Michael Burry sees a major jump. Investigate leverage rationale.
-152.72%
Less than half of AGEN's 13.64%. David Dodd sees better deleveraging or stronger cash buildup than competitor.